The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi
Speakers' Bureau - Novartis; Pfizer
Research Funding - novartis; pfizer
Travel, Accommodations, Expenses - Amgen; Novartis
 
Andre Poisl Fay
No Relationships to Disclose
 
Wanling Xie
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
Research Funding - Prometheus
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Novartis; Pfizer
 
Charles Dariane
No Relationships to Disclose
 
Guillermo De Velasco
No Relationships to Disclose
 
Renee Elizabeth Lester
No Relationships to Disclose
 
Bernard Escudier
Consulting or Advisory Role - Novartis; Pfizer
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer